Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Randomized, double-blind, multi-dose, placebo-controlled trial of fasinumab in chronic low back pain
2015-003782-28Phase 2Completed
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Feb 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in chronic low back pain (CLBP) comparing Fasinumab multi-dose with Placebo (2 arms). Primary endpoint: Change from baseline at week 16 in the average daily LBPI NRS score. Started Feb 2016; status: completed.
02
Drugs
fasinumab
03
Conditions
chronic low back pain (CLBP)
Beyond the preview
Go deeper on 2015-003782-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-003782-28.